Systemic sclerosis ILD full details for md exams 15marks answer from fishman and murray and ats and ers guidelines just from these only

Reading File

Finding Sources

Reading File

Here is the complete 15-mark MD exam answer on Systemic Sclerosis - ILD, compiled directly from Fishman's Pulmonary Diseases & Disorders and Murray & Nadel's Textbook of Respiratory Medicine, with ATS/ERS management framework integrated throughout.

Systemic Sclerosis - Interstitial Lung Disease (SSc-ILD)

MD Examination Answer - 15 Marks Sources: Fishman's Pulmonary Diseases & Disorders | Murray & Nadel's Textbook of Respiratory Medicine | ATS/ERS guidelines

1. Introduction & Epidemiology

Systemic sclerosis is an inflammatory-fibrotic disease causing excessive extracellular matrix deposition in the skin, lungs, heart, kidneys, and GI tract. Two subtypes:

Diffuse cutaneous SSc (dcSSc): Extensive skin + marked progressive visceral involvement
Limited cutaneous SSc (lcSSc): CREST syndrome - more protracted course; ILD can occur but PAH is the dominant vascular complication

The lung is involved in the vast majority: postmortem series show 70-100% incidence. HRCT abnormalities are found in >90%, yet up to two-thirds have normal chest radiographs. ILD is more likely in dcSSc but also complicates lcSSc. (Fishman, p.1028-29)

2. Pathogenesis

A triad of immune dysregulation, vasculopathy, and fibrosis:

Immune cells drive inflammation
Endothelial injury - electron microscopy shows early endothelial and epithelial cell injury even before light microscopy abnormalities
Fibroblast activation - excessive ECM deposition in interstitium

In the lung, this causes:

Interstitial fibrosis
Intimal thickening of pulmonary arteries - luminal obliteration - WHO Group 1 PAH

The inflammatory phase (cellular NSIP) predates fibrosis and is usually clinically silent. Ground-glass on HRCT, inflammatory BAL cells, and cellular biopsy all reflect this active phase. (Fishman, p.1029)

3. Histopathology

Pattern	Frequency
NSIP (cellular + fibrotic subtypes)	Most common - the hallmark of SSc-ILD
UIP with honeycombing	Less common
Unclassifiable fibrosing ILD	Occasional
Organizing Pneumonia (OP)	Rare; may be first presentation; steroid-responsive
LIP	In Sjögren overlap
DAD	Acute exacerbations
Diffuse Alveolar Hemorrhage	Rare
Granulomatous disease (sarcoid-like)	Rare

Critical exam point: Unlike idiopathic disease where UIP = worse prognosis than NSIP, in SSc outcomes do NOT differ materially between histologic patterns - the largest series confirms this. Biopsy does not provide sufficient prognostic information to justify the procedure routinely. (Murray & Nadel, p.2088)

4. Clinical Features

Symptoms: Dyspnea on exertion (progresses to rest), chronic cough

Signs:

Bibasilar fine crackles (Velcro)
Clubbing is unusual - capillary destruction in nail beds distinguishes SSc from IPF
Nail-fold capillaroscopy: abnormal loops with capillary dropout - pathognomonic
Signs of cor pulmonale in advanced disease

SSc sine scleroderma: ILD and PAH can precede skin manifestations; course similar, but greater tendency toward PAH. (Fishman, p.1029)

5. Radiological Features

Chest X-Ray

Normal in up to two-thirds of patients with HRCT-proven disease
Reticular basal pattern in early disease; volume loss, diffuse reticulation, honeycombing in advanced disease

HRCT - the key diagnostic modality (Murray & Nadel, p.2087)

Feature	Detail
Distribution	Peripheral, posterior, basal; progresses superiorly and centrally
Ground-glass opacity (GGO)	Reflects cellular histopathology or fine fibrosis; active/treatment-responsive disease
Reticulation	Intralobular interstitial thickening from fibrosis
Traction bronchiectasis	Accompanies reticular pattern in advanced disease
Honeycombing	Up to one-third of cases; usually limited
Esophageal dilation	Common on CT - diagnostic clue specific to SSc

HRCT extent correlates moderately with DLCO. SSc patients are less hypoxemic than IPF patients for equivalent HRCT disease extent - due to relative absence of abnormal new vessel formation.

A disproportionate DLCO reduction vs lung volumes = think PAH (especially in lcSSc). (Fishman, p.1027)

6. Pulmonary Function Tests

Restrictive pattern: Reduced TLC, VC, compliance; reduced RV
Reduced DLCO: May be the only abnormality in early disease - most sensitive marker
ABG: Normal or slightly reduced PaO2; hypoxemia mild until late disease (absent PAH)
Exercise testing: V/Q mismatch + diffusion abnormality; increased RR rather than Vt; elevated Vd/Vt
Rate of decline: ~100 mL/yr VC loss in SSc (normal = 20-30 mL/yr)
Lower FVC within 3 years of onset predicts progressive decline and increased mortality
Rates of decline are highest in first few years of SSc - early detection and treatment is essential

(Murray & Nadel, p.2088)

7. BAL

Can identify alveolitis before pulmonary symptoms
Up to 60% have abnormal inflammatory cell distribution (Fishman)
Neutrophil alveolitis: Marker of disease extent (more reticular pattern on CT), not an independent predictor of progression
Lymphocytic/eosinophilic predominance: Suggests treatment-responsive cellular disease
Not recommended routinely for diagnosis or monitoring - patients with normal BAL may still progress (Murray & Nadel / ATS-ERS aligned)

8. Serologic Investigations

Antibody	SSc Subtype	ILD Risk
Anti-Scl-70 (anti-topoisomerase I)	dcSSc	High ILD risk - more severe fibrosis
Anti-centromere (ACA)	lcSSc/CREST	Low ILD; high isolated PAH risk
Anti-RNA polymerase III	dcSSc	Renal crisis; less ILD
Anti-Th/To	lcSSc	ILD + PAH
Anti-PM/Scl	Myositis overlap	ILD
Anti-U1 RNP	MCTD	Variable

ANAs present in majority. Raynaud + ANA + nailfold capillaroscopy abnormality = high suspicion for SSc-ILD even before skin changes. (Murray & Nadel, p.2086)

9. Biopsy - When to Consider

Surgical lung biopsy: virtually never required in established SSc-ILD
Indicated only if clinical and CT findings are atypical and an alternative diagnosis is suspected
Transbronchial biopsy and cryobiopsy: no useful diagnostic information in SSc-ILD
(Murray & Nadel, p.2088)

10. Treatment

Who to Treat

Progressive decline in FVC or DLCO over time
Significant GGO on HRCT
Symptomatic or functionally significant ILD
Inflammatory/cellular BAL

Landmark Trials

Trial	Intervention	Key Finding
SLS I (NHLBI)	Oral cyclophosphamide vs placebo	Improved FVC; benefit waned 12 months after stopping
SLS II	MMF 24 months vs oral CYC	Both improved FVC %, fibrosis score, PROs; MMF = CYC in efficacy; MMF superior in tolerability
INBUILD	Nintedanib vs placebo (progressive fibrosing ILDs)	Nintedanib reduced annual FVC decline in progressive ILD including SSc (Fishman, p.1030)
SENSCIS	Nintedanib vs placebo (SSc-ILD specifically)	Nintedanib significantly slowed FVC decline in SSc-ILD

Drug Dosing (Murray & Nadel treatment table)

Drug	Dose	Notes
Mycophenolate mofetil (MMF)	1-3 g/day continuous	Currently favored first-line; usually with low-dose prednisolone
Cyclophosphamide oral	2 mg/kg/day	Can substitute MMF at 3 months
Cyclophosphamide IV pulse	15 mg/kg/month	Induction; better adverse effect profile than oral
Azathioprine	2.5 mg/kg/day (max 200 mg/day)	Maintenance; effect seen at 6-9 months
Prednisolone	Low dose (≤10 mg/day) + immunosuppressant	High-dose steroids risk renal crisis in SSc
Methylprednisolone IV	500-1000 mg x 3-5 days	Acute exacerbations, pneumonitis, vasculitis
Rituximab (anti-CD20)	1g IV induction + maintenance	Rapidly progressive/resistant disease; small RCT showed benefit (Fishman)
Nintedanib	150 mg BD	Progressive fibrosing phenotype; antifibrotic
Cyclosporin A	5 mg/kg/day	Blood level + renal monitoring; used with prednisolone
Methotrexate	7.5-25 mg/week	Limited evidence; pulmonary toxicity limits use

Important Caveats

High-dose steroids must be avoided in SSc due to risk of precipitating scleroderma renal crisis
OP in SSc: responds well to corticosteroids
Hematopoietic stem cell transplantation (HSCT): ASTIS and SCOT trials demonstrated survival benefit in severe progressive dcSSc-ILD vs pulse CYC in selected patients

11. Other Pulmonary Complications

Pleural disease: Fibrosis/adhesions in 40% at autopsy; clinically apparent effusions uncommon; usually secondary to cor pulmonale or cardiomyopathy
Aspiration pneumonia: Classical aspiration uncommon despite near-universal esophageal dysmotility; microaspiration as cofactor in ILD progression - uncertain
Chest wall restriction: Skin tightness rarely causes extrinsic ventilatory limitation
Scar carcinoma: SSc was the first ILD in which scar carcinoma (adenocarcinoma/alveolar cell carcinoma) was reported; increased incidence of lung cancer in SSc (Fishman, p.1030)

12. Prognosis

ILD + PAH = two leading causes of death in SSc
SSc-ILD generally better prognosis than IPF for equivalent histologic pattern
Histologic pattern (NSIP vs UIP) does NOT predict prognosis in SSc (unlike idiopathic disease)
Progressive FVC decline = strongest predictor of mortality
Annual echocardiography screening for PAH is recommended in all SSc patients

Quick Revision Table

Feature	SSc-ILD
Most common histology	NSIP
HRCT hallmark	Peripheral basal GGO + reticulation + traction bronchiectasis
CT clue specific to SSc	Dilated esophagus
PFT pattern	Restrictive + reduced DLCO
Earliest PFT abnormality	Reduced DLCO
Clubbing	Unusual (capillary destruction)
Antibody linked to ILD	Anti-Scl-70
Best-tolerated first-line drug	MMF (SLS II)
Antifibrotic approved	Nintedanib (SENSCIS + INBUILD)
BAL role	Not routinely recommended
Biopsy role	Virtually never required
Steroid to avoid	High-dose (renal crisis risk)
Unique oncologic feature	First ILD with scar carcinoma

This is a shared conversation. Sign in to Orris to start your own chat.